Contract development and manufacturing organisation (CDMO) Bora has opened its first North American office in Delaware, the company has announced.
The complex modified release (MR) products specialist opened the office as part of a two-year plan to invest in the North American market.
In recent years, Bora has invested over $60 million in acquiring global facilities to help it expand outside of Asia. The announcement follows recent reports of Bora’s fifth successful FDA inspection at its facility in Taiwan.
“Opening an office on the East coast of the US, is a significant milestone for our organisation and signals our continued commitment to the region. The office is one phase of our expansion plans, as we continue to explore acquisition opportunities in the market. It will not only support our own future growth strategy but also allows us to better support our growing client base, as companies across the US continue to outsource their most complex oral solid dose (OSD) projects to Bora,” said Bobby Sheng, CEO at Bora Pharmaceuticals.